论文部分内容阅读
目的探讨胃癌腹水患者血清IL-6检测在化疗疗效评估中的意义。方法采用酶联免疫吸附测定法(双抗体夹心法)动态检测39例胃癌腹水患者化疗前后血清IL-6的变化,选择20例正常人群作为对照。结果胃癌腹水患者血清IL-6水平明显高于正常人[(245.886±3.653)ng/Lvs.(41.940±2.031),P<0.05];化疗疗效为完全缓解(CR)及部分缓解(PR)的患者,血清IL-6水平较化疗前明显下降(P<0.05),化疗疗效为进展(PD)的患者,化疗后血清IL-6水平明显上升(P<0.05)。结论胃癌腹水患者血清IL-6水平检测可作为评价胃癌腹水病情和疗效的辅助指标。
Objective To investigate the significance of detection of serum IL-6 in patients with ascites of gastric cancer in evaluating the curative effect of chemotherapy. Methods Serum IL-6 levels were measured by enzyme linked immunosorbent assay (double antibody sandwich method) in 39 patients with ascites of gastric cancer before and after chemotherapy. Twenty normal controls were selected as the control group. Results Serum levels of IL-6 in patients with gastric cancer ascites were significantly higher than those in normal controls [(245.886 ± 3.653) ng / L vs (41.940 ± 2.031), P <0.05]. The response to chemotherapy was complete remission (CR) and partial remission The levels of serum IL-6 in patients and patients were significantly lower than those before chemotherapy (P <0.05). The patients with progressive chemotherapy (PD) had significantly higher serum IL-6 levels after chemotherapy (P <0.05). Conclusion The detection of serum IL-6 in patients with ascites from gastric cancer can be used as an auxiliary index to evaluate the condition and efficacy of gastric cancer ascites.